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Abstract A selective cyclic nucleotide PDE5 inhibitor corrected
the defective mucin secretion response to the L-agonist iso-
proterenol in submandibular acinar cells inhibited by antibody
directed against the cystic fibrosis transmembrane conductance
regulator. The PDE5 inhibitor was as effective as cpt-cyclic
AMP or a selective PDE4 inhibitor. However, the PDE5
inhibitor had no effect on basal or isoproterenol-stimulated cyclic
AMP levels and did not stimulate mucin secretion. The results
showing, for the first time, correction of the CFTR mucin
secretion defect by a PDE5 inhibitor, which may involve cyclic
GMP, will have a major impact in development of a rational drug
treatment for cystic fibrosis.
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1. Introduction
Cystic ¢brosis (CF) is an autosomal recessive disease char-
acterised by disturbances in ion transport and viscous epithe-
lial mucous secretions [1,2]. The cystic ¢brosis gene protein,
the cystic ¢brosis transmembrane conductance regulator pro-
tein (CFTR), acts as a Cl3 channel [3] and we have shown it
to be a key regulator of protein secretion [4^8]. Thus, an
antibody raised against a synthetic peptide from the ¢rst nu-
cleotide-binding domain (NBD) of CFTR inhibited L-adrener-
gic-stimulated mucin secretion, when introduced into living
rat submandibular cells by hypotonic swelling [4]. The cells
containing CFTR antibody showed the same phenotype as
submandibular gland cells from CF individuals [5^7] and
CF mice [8]. In addition, we have shown that the defective
L-adrenergic stimulation of mucin secretion in CF cells and in
CFTR antibody-containing cells was corrected to the same
degree by 3-isobutyl-1-methylxanthine (IBMX), a non-selec-
tive cyclic nucleotide PDE inhibitor [4^8]. The CFTR anti-
body submandibular cell thus provides a good model for in-
vestigating correction of the CFTR defect [4,9]. Other studies
in agreement showed that an antibody raised against an ad-
jacent peptide sequence in CFTR inhibited cyclic AMP-de-
pendent Cl3 transport [10] and that epithelial cells transfected
with CFTR showed increased cyclic AMP-dependent endocy-
tosis and exocytosis [11] and mucin secretion [12,13].
Cyclic nucleotide phosphodiesterases can be classi¢ed into
seven distinct families, on the basis of their substrate, regula-
tion, and sensitivity to pharmacological agents [14]. The non-
selective PDE inhibitor, IBMX, and other more selective PDE
inhibitors have been used to investigate whether they activate
CFTR-mediated Cl3 transport. IBMX activated Cl3 trans-
port in Xenopus oocytes expressing the most common mutant
form of CFTR, vF508-CFTR, which has a 3-bp deletion
leading to loss of a phenylalanine residue [15,16]. An inhibitor
of PDE3 (cyclic GMP-inhibited), milrinone, activated Cl3
transport in homozygous vF508 CF cells in vitro [17]
although IBMX and a PDE4 (cyclic AMP-speci¢c) inhibitor
were ine¡ective [17,18]. Milrinone increased nasal potential
di¡erence, which re£ects Cl3 transport in vivo, in CF mice
[19] but not in CF patients [20]. It is essential to clarify the
role of selective PDE inhibitors in restoration of mutant
CFTR activity using a well-characterised cell model. Further-
more, evidence suggests that improved CFTR-mediated Cl3
transport, measured by changes in nasal potential di¡erence in
vivo, does not necessarily correlate with improvement of CF
symptoms [21]. The CFTR-mediated mucin secretion defect is
likely to be fundamental to the development of the clinical
manifestations of CF and may thus provide a means of eval-
uating e⁄cacy of new pharmacological agents for CF [22,23].
We have now studied, for the ¢rst time, the actions of selec-
tive PDE inhibitors on CFTR antibody-inhibited mucin secre-
tion, to investigate the mechanism of correction of defective
CFTR function and the involvement of cyclic AMP and cyclic
GMP.
2. Materials and methods
2.1. Production of anti-peptide CFTR antibodies
Antibodies were raised against a peptide consisting of 14 amino
acids (524^537), residing in the NBD1 region of CFTR [16] and af-
¢nity-puri¢ed as previously described [4,9]. The peptide sequence used
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(CQLEEDISKFAEKD) was unique to human and bovine CFTR
(SwissProt database, BLASTP and FASTA3_T, 1997). The rat
CFTR sequence (CQLQEDITKFAEQD) has 11 identical and three
conserved amino acids; the mouse sequence is identical to rat, but
with an additional change (Q at position 5) from rat and human. The
antibody has been shown to cross-react speci¢cally with rat and
mouse CFTR in native submandibular and pancreatic tissues [4]
and with mouse CFTR expressed in CHO cells [9].
2.2. Isolation of rat submandibular acini, incorporation of antibodies
into intact acini and measurement of mucin secretion
Procedures were carried out as previously described [4,9,24]. Brie£y,
acini were pulse-chase labelled with [3H]glucosamine (5 WCi/ml) and
suspended in TES-bu¡ered saline (10 mM TES, pH 7.4 containing 143
mM NaCl, 4.7 mM KCl, 1.1 mM MgCl2, 1 mg/ml bovine serum
albumin). To 200 Wl of acini suspension, 800 Wl of either 10 mM
TES, pH 7.4 (swollen) or TES-bu¡ered saline (unswollen), each con-
taining 5 mM ATP and CFTR antibody or non-immune IgG (approx.
1 mg IgG/ml) was added for 1.5 min at room temperature, followed
by washing and resuspension in KHB bu¡er (see [4,24]) containing 20
mg/ml bovine serum albumin. Following a 15 min recovery incubation
at 37‡C in KHB bu¡er, acini were washed and incubated under ex-
perimental conditions at 37‡C. Isoproterenol and IBMX (Sigma) were
dissolved directly into KHB medium at the concentrations used; the
selective PDE3, 4 and 5 inhibitors were dissolved initially in DMSO
and diluted to give a ¢nal concentration of 6 1% DMSO in the
incubations. An equivalent amount of DMSO was added to control
incubations. The PDE5 inhibitor was the least soluble, hence a con-
centration of 0.2 mM, rather than 1 mM was used. [3H]Glucosamine-
labelled mucins, released into the medium at zero time and after 30
min and in aliquots of cells at zero time, were acid-precipitated using
a combination of 10% trichloroacetic acid (TCA) and 0.5% phospho-
tungstic acid (PTA). The precipitates were washed three times in
TCA/PTA (10%/0.5%) at 4‡C and their radioactivity measured as
previously described [4,9,24]. The radioactively labelled secreted pro-
teins measured in this way have been characterised as mucins [9].
The protein content of cell pellets was determined using the Bio-
Rad protein assay kit and mucin release over 30 min expressed as
dpm/mg protein or as % basal secretion to take account of variation
in unstimulated mucin release between experiments. Isoproterenol se-
cretory responses are relatively consistent within a series of experi-
ments but can vary (see Tables 1, 2 and Fig. 2) between series, as has
been published previously [9,25]. Degree of correction was calculated
by expressing the di¡erence between isoproterenol response in CFTR
antibody-inhibited cells in the presence or absence of PDE inhibitor
or cpt-cyclic AMP as a percentage of the di¡erence in isoproterenol
response between non-immune IgG and CFTR antibody-containing
cells.
2.3. Measurement of cyclic AMP and cyclic GMP content
Aliquots of acini suspensions (0.5 ml) were added to an equal vol-
ume of ice-cold TCA (20%), extracted and assayed using speci¢c ra-
dioimmunoassay kits for cyclic AMP and cyclic GMP (Amersham), as
previously described [4].
3. Results
3.1. Structure of selective cyclic nucleotide PDE inhibitors
The mechanism of action of IBMX in correcting defective
CFTR function was investigated using selective PDE3 (SB
95654) [26], PDE4 (rolipram, SB 95952) and PDE5
(SB96231) [27] inhibitors. Their structures are shown in Fig.
1 and compared to that of the non-selective PDE inhibitor,
IBMX. Of the selective inhibitors used, only SB 96231 pos-
sesses a xanthine ring structure but with di¡erent side groups,
i.e. propoxyphenol at the 2 position rather than the 1-methyl,
3-isobutyl substitutions of IBMX.
3.2. Actions of PDE inhibitors on mucin secretion and cyclic
AMP
The actions of selective cyclic nucleotide PDE inhibitors on
mucin secretion and cyclic AMP rise from submandibular
acini have been compared with maximum responses elicited
by the L-adrenergic agonist isoproterenol and the non-selec-
tive PDE inhibitor IBMX (Table 1). The PDE3 and PDE5
inhibitors did not signi¢cantly increase cyclic AMP or mucin
secretion. The PDE4 inhibitor (1 mM) gave the same cyclic
AMP rise as isoproterenol but was much less e¡ective in stim-
ulating mucin secretion. By contrast, IBMX (1 mM) stimu-
lated mucin secretion to the same extent as isoproterenol but
gave a much lower cyclic AMP rise. The data indicate a lack
Table 1
Actions of PDE inhibitors on mucin secretion and cyclic AMP lev-





No addition 100 þ 9 9.4 þ 2.7
Isoproterenol 619 þ 101** 160.3 þ 23.1!!
IBMX 578 þ 84** 27.9 þ 4.9!
PDE3 inhibitor 139 þ 42 11.8 þ 1.7
PDE4 inhibitor 191 þ 20* 168.2 þ 36.6!
PDE5 inhibitor 122 þ 35 4.9 þ 06
Mucin release was measured at 30 min and cyclic AMP at 5 min as
described in Section 2, in the presence or absence of isoproterenol
(10 WM) or PDE inhibitors (IBMX, PDE3 and PDE4 at 1 mM;
PDE5 at 0.2 mM). Mucin release is expressed as % basal, due to
the variation in basal secretion between experiments. The range of
basal mucin secretion was 414^653 dpm/mg protein. Basal secretion
was 3.7 þ 0.3% (mean þ S.E.M., n = 3) of the total labelled mucin
pool, as determined by expressing the amount of labelled mucins in
the medium as a percentage of the total labelled mucins in the cells.
Results are mean þ S.E.M. for at least three experiments. Signi¢-
cance of di¡erences was assessed by Student’s t-test: *P6 0.002;
**P6 0.001 for di¡erence from basal mucin secretion; !P6 0.05;
!!P6 0.01 for di¡erence from basal cyclic AMP.
Fig. 1. Structure of PDE inhibitors. A: 3-Isobutyl-1-methylxanthine
(IBMX). B: SB 95952 (4-(3-cyclopentyloxy-4-methoxyphenyl)-2-pyr-
rolidinone). C: SB 95654 (R,S,-4,5-dihydro-6-[4-(1,4-dihydro-4-oxo-
pyriiny-1-yl)phenyl]-5-methyl-3(2H)-pyridazinone). D: SB 96231
(1,7-dihydro-2-(2-propoxyphenyl)-6H-purin-6-one).
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of correlation between magnitude of increase in cyclic AMP
and stimulation of mucin secretion and are in accord with our
previous results [25,28].
3.3. Correction of CFTR submandibular mucin secretion
response
We have assessed the actions of selective cyclic nucleotide
PDE inhibitors in correcting the defective isoproterenol-
stimulated mucin secretion in CFTR antibody-containing sub-
mandibular cells (Fig. 2) and compared their e⁄cacy to that
of cpt-cyclic AMP. PDE4 and PDE5 inhibitors partially cor-
rected the defective mucin secretion response. Although the
mean value was lower, the degree of correction by the PDE4
inhibitor was not signi¢cantly di¡erent from that of the PDE5
inhibitor. The PDE3 inhibitor was ine¡ective. The PDE5 in-
hibitor (0.2 mM) was as e¡ective as cpt-cyclic AMP (1 mM)
which was previously shown to restore the mucin secretion
response of CFTR antibody-inhibited cells to approximately
70^80% of non-immune IgG-containing cells [4]. The current
results (Fig. 2) also show that cpt-cyclic AMP restored CFTR
antibody-inhibited mucin secretion to 79% (mean) and the
PDE5 inhibitor to 75% (mean) of that seen in non-immune
IgG-containing cells. Although unswollen cells had a higher
mean isoproterenol secretory response than non-immune IgG-
containing cells (Fig. 2, legend), the di¡erence was as shown
previously [4] not signi¢cant.
3.4. Cyclic AMP rise in the presence of isoproterenol
We have measured correction of the CFTR mucin secretion
response in CF cells or CFTR antibody-containing cells in the
presence of isoproterenol, since the L-adrenergic response is
defective. Thus, e¡ects of PDE inhibitors on cyclic AMP lev-
els in the presence of the L-agonist isoproterenol are shown
(Table 2), to indicate whether they potentiate cyclic AMP rise
and give increases in cyclic AMP above the levels induced
physiologically by L-adrenergic stimulation. Our previous re-
sults have shown that the cyclic AMP response of non-swollen
cells or cells swollen in the presence of either non-immune IgG
or CFTR antibody were not di¡erent [4]. None of the selective
PDE inhibitors nor IBMX signi¢cantly increased mucin secre-
tion above the maximum response induced by isoproterenol
alone (Table 2) and the lack of e¡ect was not due to exhaus-
tion of the labelled mucin pool. The results indicate that iso-
proterenol and the PDE inhibitors stimulate mucin secretion
by a common pathway which we have shown to be CFTR-
mediated [4,8,9]. However, IBMX, PDE3 and PDE4 inhibi-
tors markedly potentiated the isoproterenol-induced cyclic
AMP rise. The PDE3 inhibitor was as e¡ective as IBMX
(Table 2), although it did not correct CFTR mucin secretion
activity (Fig. 2). By contrast, the PDE5 inhibitor did not
potentiate isoproterenol-induced cyclic AMP rise, but cor-
rected defective CFTR function.
3.5. Role of cyclic GMP in correction of defective CFTR
function
We have examined the actions of the PDE5 inhibitor on
cyclic GMP levels to investigate whether cyclic GMP plays a
role in correction of CFTR-mediated mucin secretion. Isopro-
Table 2
Actions of PDE inhibitors on isoproterenol-stimulated mucin secretion and cyclic AMP levels in rat submandibular acini
Addition Mucin secretion (% basal) Cyclic AMP (pmol/mg protein)
No adddition 100 þ 7 7.9 þ 1.9
Isoproterenol 785 þ 212 373.0 þ 84.0
Isoproterenol+IBMX 924 þ 290 1252.9 þ 129.6*
Isoproterenol+PDE3 inhibitor 692 þ 238 1009.6 þ 91.5*
Isoproterenol+PDE4 inhibitor 708 þ 220 1908.7 þ 150.8**
Isoproterenol+PDE5 inhibitor 755 þ 243 375.5 þ 95.8
Mucin secretion was measured at 30 min and cyclic AMP at 5 min as described in Section 2, in the presence or absence of isoproterenol
(10 WM) and PDE inhibitors (IBMX, PDE3 and PDE4 at 1 mM; PDE5 at 0.2 mM), under the conditions shown. Mucin secretion is expressed
as % basal, due to the variation in basal secretion between experiments. The range of basal mucin secretion was 232^974 dpm/mg protein.
Basal mucin secretion was 3.6 þ 0.3% (mean þ S.E.M., n = 6) and isoproterenol-stimulated mucin secretion was 28.3 þ 7.6% (mean þ S.E.M.,
n = 6) of the total labelled mucin pool, as determined by expressing the amount of labelled mucins in the medium as a percentage of the total
labelled mucins in the cells. Results are mean þ S.E.M. for six experiments. Signi¢cance of di¡erences was assessed by Student’s t-test.
*P6 0.001; **P6 0.0001 for di¡erence from stimulation by isoproterenol alone.
Fig. 2. Correction of CFTR antibody-inhibited L-adrenergic stimula-
tion of mucin secretion by PDE inhibitors. Rat submandibular acini
were pulse-chase labelled with [3H]glucosamine and swollen in the
presence of CFTR antibody as described in Section 2. Mucin secre-
tion in the presence of isoproterenol (Iso, 10 WM) and PDE inhibi-
tors (PDE3 and PDE4 inhibitors at 1 mM; PDE5 inhibitor at
0.2 mM) or cpt-cyclic AMP (1 mM) as shown, was measured after
30 min. Mucin secretion in response to isoproterenol (10 WM) in un-
swollen cells was 353.7 þ 45.4 (mean þ S.E.M., n = 4) % basal and in
cells swollen in the presence of non-immune IgG it was 284.8 þ 42.1
(mean þ S.E.M., n = 5; P6 0.02 for di¡erence from cells swollen in
the presence of CFTR antibody). Results are mean þ S.E.M. for at
least four experiments and are expressed as % basal. *P6 0.05,
**P6 0.01 for di¡erence from secretion in the presence of isoproter-
enol alone as assessed by Student’s t-test.
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terenol alone caused a small increase in cyclic GMP, which
was further increased in the presence of IBMX or the selective
PDE5 inhibitor (Table 3). The PDE5 inhibitor alone also gave
a signi¢cant increase in cyclic GMP (Table 3). IBMX and the
PDE5 inhibitor also increased cyclic GMP levels in the pres-
ence of the cholinergic agonist carbamylcholine. Thus, cyclic
GMP levels were increased from 32.5, 40.3 (n = 2) fmol/mg
protein in the presence of carbamylcholine (50 WM) alone to
91.9, 101.4 (n = 2) fmol/mg protein in the presence of carba-
mylcholine (50 WM)+IBMX (1 mM) and to 102.4, 117.0
(n = 2) fmol/mg protein in the presence of carbamylcholine
(50 WM)+PDE5 inhibitor (0.2 mM). The PDE3 and PDE4
inhibitors did not change cyclic GMP levels in the presence
or absence of isoproterenol (Table 3).
The data showing lack of correction of CFTR mucin secre-
tion activity by a PDE3 inhibitor indicate that potentiation of
isoproterenol-induced cyclic AMP rise alone is not su⁄cient
to correct CFTR function. In addition, a PDE5 inhibitor that
did not increase isoproterenol-induced cyclic AMP rise cor-
rected the CFTR mucin secretion defect and, like IBMX,
potentiated the L-agonist-induced cyclic GMP rise.
4. Discussion
We have shown that a selective cyclic nucleotide PDE5
inhibitor partially corrected defective L-adrenergic stimulation
of mucin secretion in CFTR antibody-inhibited submandibu-
lar cells. The PDE5 inhibitor did not increase cyclic AMP
levels, nor did it potentiate isoproterenol-induced cyclic
AMP rise. To our knowledge this is the ¢rst demonstration
that the CFTR mucin secretion defect can be corrected by a
PDE5 inhibitor, which increases cyclic GMP but not cyclic
AMP levels.
A lack of correlation between magnitude of increase in
cyclic AMP and stimulation of mucin secretion in submandib-
ular cells was observed in that isoproterenol and IBMX max-
imally stimulated mucin secretion, but IBMX gave a much
lower cyclic AMP response and a PDE4 inhibitor increased
cyclic AMP to the same extent as isoproterenol, but gave
much less stimulation of mucin secretion. The data agree
with our previous results [25,28] showing dissociation between
cyclic AMP rise and mucin secretion and indicate that this is
not the sole intracellular messenger involved. The ¢nding that
isoproterenol increased intracellular Ca2 in acini populations
[29] and that intracellular BAPTA inhibited secretion in re-
sponse to isoproterenol [25] suggested that intracellular Ca2
may play an important role. Stimulation of wild-type mucin
secretion was not a prerequisite for correction of CFTR ac-
tivity, as shown by the lack of stimulation of mucin secretion
by the active PDE5 inhibitor.
Our studies are in agreement with others showing correc-
tion of CFTR Cl3 transport by IBMX but not by a PDE3
inhibitor [15,20]. However, other investigators have reported
restoration of Cl3 transport by PDE3 but not by IBMX or
PDE4 inhibition [17,18]. The present cell model has directly
examined correction of isoproterenol-induced CFTR anti-
body-inhibited mucin secretion. A structurally related com-
pound, 8-cyclopentyl theophylline, also corrected CFTR anti-
body-inhibited mucin secretion [9] but did not activate wild-
type CFTR Cl3 channels [30]. IBMX and the PDE4 inhibitor
increased cyclic AMP and potentiated isoproterenol-induced
cyclic AMP rise. However, the PDE3 inhibitor showed the
same isoproterenol-induced cyclic AMP rise as IBMX but
no correction of mucin secretion suggesting that increases in
cyclic AMP alone are not su⁄cient to correct CFTR anti-
body-inhibited mucin secretion. A similar lack of correlation
between increases in cyclic AMP and stimulation of Cl3
transport, induced by PDE3 and PDE4 inhibitors, was ob-
served in a homozygous vF508 CF airways epithelial cell
line [17].
The ¢nding that a PDE5 inhibitor corrected CFTR anti-
body-inhibited mucin secretion raised the question as to
whether cyclic GMP was involved. The results showing that
the PDE5 inhibitor stimulated basal, isoproterenol- and car-
bamylcholine-induced cyclic GMP levels indicate the presence
of an active PDE5 in submandibular acini, although this has
yet to be con¢rmed by direct identi¢cation of the enzyme. The
role of cyclic GMP in stimulation of protein secretion and ion
transport in submandibular acini is not clear. Thus, the
present data showed a small elevation of cyclic GMP in re-
sponse to isoproterenol, which was further increased in the
presence of IBMX or a PDE5 inhibitor. However, in agree-
ment with early studies [31,32], the increases were less than
those induced by carbamylcholine in the presence of a PDE
inhibitor (see Section 3). Although cyclic GMP increases in
response to the most potent stimulator of mucin secretion,
isoproterenol, are small, it is possible that either cyclic AMP
or cyclic GMP can activate CFTR to induce stimulation of
mucin secretion. Thus, in addition to the well-established ac-
tivation of CFTR by cyclic AMP-activated protein kinase [3],
the type II, membrane-associated cyclic GMP-activated pro-
tein kinase has been shown to phosphorylate CFTR and acti-
vate Cl3 transport in rat intestinal cells expressing CFTR [33].
In addition, although the C-type natriuretic peptide, which
increased cyclic GMP levels in airways epithelial cells [34],
did not stimulate ion transport in human cultured surface
epithelial cells [35] it did increase Cl3 transport in mouse
nasal epithelium [36] and in a human airways gland cell line
[37]. Thus, although correction by the PDE5 inhibitor could
be mediated by cyclic GMP, the lack of e¡ect of the PDE4
inhibitor on cyclic GMP (Table 3) suggests that other actions,
such as a Ca2-dependent mechanism or interaction of the
PDE inhibitors with CFTR may be involved. The results of
the present study suggest that the actions of the selective
Table 3
Actions of PDE inhibitors on cyclic GMP levels in the presence or
absence of isoproterenol
Addition Cyclic GMP (fmol/mg protein)
No isoproterenol +Isoproterenol
(10 WM)
No addition 39.2 þ 1.0 (6) 45.2 þ 1.6 (4)
IBMX (1 mM) 48.1 þ 5.2 (8) 55.6 þ 1.6** (8)
PDE3 inhibitor (1 mM) 39.3 þ 2.4 (3) 47.0 þ 1.8 (4)
PDE4 inhibitor (1 mM) 40.1 þ 1.5 (3) 45.2 þ 2.0 (4)
PDE5 inhibitor (0.2 mM) 47.3 þ 2.5* (5) 64.3 þ 3.6** (5)
Cyclic GMP levels were measured as described in Section 2 follow-
ing 5 min incubation under the conditions shown. PDE inhibitor
concentrations used were 1 mM for IBMX, PDE3 and PDE4 and
0.2 mM for PDE5. Results are mean þ S.E.M. for the number of ex-
periments shown in parentheses. Signi¢cance of di¡erences was as-
sessed by Student’s t-test. *P6 0.02 for di¡erence from basal cyclic
GMP (no isoproterenol); all conditions in the presence of isoproter-
enol were signi¢cantly di¡erent from basal cyclic GMP (P6 0.05);
**P6 0.005 for di¡erence from stimulation by isoproterenol alone.
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PDE5 inhibitor should be investigated on CF mouse and hu-
man cells to further elucidate the mechanisms involved and to
evaluate their potential for use in CF patients.
The ¢nding, for the ¢rst time, that correction of the CFTR
mucin secretion defect can be achieved by a selective PDE5
inhibitor is likely to have major impact for CF therapy. Thus,
in view of its e⁄cacy as a weak bronchodilator [27], its spe-
ci¢city, in that it does not increase cyclic AMP and it being
one of a class of PDE5 inhibitors which includes Viagra0,
this would provide a relatively safe compound in the develop-
ment of a selective pharmacological therapy for cystic ¢brosis
targeted at the gene protein defect.
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